title: Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.
abstract: The serotonin-2A receptor (5-HT(2A)R) has been implicated in the pathogenesis of schizophrenia and related inhibitory gating and behavioral inhibition deficits of schizophrenia patients. The hallucinogen psilocybin disrupts automatic forms of sensorimotor gating and response inhibition in humans, but it is unclear so far whether the 5-HT(2A)R or 5-HT(1A)R agonist properties of its bioactive metabolite psilocin account for these effects. Thus, we investigated whether psilocybin-induced deficits in automatic and controlled inhibition in healthy humans could be attenuated by the 5-HT(2A/2C)R antagonist ketanserin. A total of 16 healthy participants received placebo, ketanserin (40 mg p.o.), psilocybin (260 μg/kg p.o.), or psilocybin plus ketanserin in a double-blind, randomized, and counterbalanced order. Sensorimotor gating was measured by prepulse inhibition (PPI) of the acoustic startle response. The effects on psychopathological core dimensions and behavioral inhibition were assessed by the altered states of consciousness questionnaire (5D-ASC), and the Color-Word Stroop Test. Psilocybin decreased PPI at short lead intervals (30 ms), increased all 5D-ASC scores, and selectively increased errors in the interference condition of the Stroop Test. Stroop interference and Stroop effect of the response latencies were increased under psilocybin as well. Psilocybin-induced alterations were attenuated by ketanserin pretreatment, whereas ketanserin alone had no significant effects. These findings suggest that the disrupting effects of psilocybin on automatic and controlled inhibition processes are attributable to 5-HT(2A)R stimulation. Sensorimotor gating and attentional control deficits of schizophrenia patients might be due to changes within the 5-HT(2A)R system.
authors.affiliation: Neuropsychopharmacology and Brain Imaging, Clinic of Affective Disorders and General Psychiatry, University Hospital of Psychiatry, Heffter Research Center, Zürich, Switzerland.
authors.forename: Boris B
authors.initials: BB
authors.lastname: Quednow
authors.forename: Michael
authors.initials: M
authors.lastname: Kometer
authors.forename: Mark A
authors.initials: MA
authors.lastname: Geyer
authors.forename: Franz X
authors.initials: FX
authors.lastname: Vollenweider
mesh_terms: D000161:Acoustic Stimulation; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006213:Hallucinogens / Q000494:pharmacology*; D006801:Humans; D007266:Inhibition, Psychological; D007650:Ketanserin / Q000494:pharmacology*; D008297:Male; D009483:Neuropsychological Tests; D011562:Psilocybin / Q000494:pharmacology*; D013216:Reflex, Startle / Q000187:drug effects; D055139:Sensory Gating / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology*; D011795:Surveys and Questionnaires
chemical_list: D006213:Hallucinogens; D012702:Serotonin Antagonists; D011562:Psilocybin; D007650:Ketanserin